ALX Oncology Holdings Inc has a consensus price target of $32.88 based on the ratings of 9 analysts. The high is $106 issued by Stifel on September 30, 2021. The low is $14 issued by Stifel on March 8, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 10, 2024, April 10, 2024, and March 11, 2024, respectively. With an average price target of $21.67 between HC Wainwright & Co., there's an implied 276.81% upside for ALX Oncology Holdings Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/10/2024 | Buy Now | 334.78% | HC Wainwright & Co. | Swayampakula Ramakanth | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
05/29/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek | — | Reiterates | → Overweight | Get Alert |
04/12/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek | — | Reiterates | → Overweight | Get Alert |
04/10/2024 | Buy Now | 247.83% | HC Wainwright & Co. | Swayampakula Ramakanth | → $20 | Reiterates | Buy → Buy | Get Alert |
03/11/2024 | Buy Now | 247.83% | HC Wainwright & Co. | Swayampakula Ramakanth | $17.5 → $20 | Maintains | Buy | Get Alert |
03/08/2024 | Buy Now | 143.48% | Stifel | Bradley Canino | $10 → $14 | Downgrade | Buy → Hold | Get Alert |
03/08/2024 | Buy Now | 265.22% | Piper Sandler | Christopher Raymond | $11 → $21 | Maintains | Overweight | Get Alert |
12/08/2023 | Buy Now | 213.04% | Jefferies | Michael Yee | $8 → $18 | Upgrade | Hold → Buy | Get Alert |
11/14/2023 | Buy Now | 73.91% | Stifel | Bradley Canino | $11 → $10 | Maintains | Buy | Get Alert |
10/11/2023 | Buy Now | 91.3% | Piper Sandler | Christopher Raymond | $8 → $11 | Maintains | Overweight | Get Alert |
10/04/2023 | Buy Now | 369.57% | UBS | Colin Bristow | $29 → $27 | Maintains | Buy | Get Alert |
10/04/2023 | Buy Now | 300% | Cantor Fitzgerald | Li Watsek | $18 → $23 | Maintains | Overweight | Get Alert |
10/03/2023 | Buy Now | 204.35% | HC Wainwright & Co. | Swayampakula Ramakanth | $16 → $17.5 | Reiterates | Buy → Buy | Get Alert |
09/12/2023 | Buy Now | 213.04% | Cantor Fitzgerald | Alethia Young | → $18 | Reiterates | Overweight → Overweight | Get Alert |
09/07/2023 | Buy Now | 213.04% | Cantor Fitzgerald | Alethia Young | → $18 | Reinstates | Overweight → Overweight | Get Alert |
08/14/2023 | Buy Now | 213.04% | Cantor Fitzgerald | Alethia Young | $22 → $18 | Maintains | Overweight | Get Alert |
08/11/2023 | Buy Now | 213.04% | Cantor Fitzgerald | Alethia Young | $22 → $18 | Maintains | Overweight | Get Alert |
08/11/2023 | Buy Now | 39.13% | Piper Sandler | Christopher Raymond | $48 → $8 | Maintains | Overweight | Get Alert |
08/11/2023 | Buy Now | 178.26% | HC Wainwright & Co. | Swayampakula Ramakanth | $30 → $16 | Maintains | Buy | Get Alert |
07/24/2023 | Buy Now | 282.61% | Cantor Fitzgerald | Alethia Young | → $22 | Reiterates | Overweight → Overweight | Get Alert |
05/12/2023 | Buy Now | 421.74% | HC Wainwright & Co. | Swayampakula Ramakanth | → $30 | Reiterates | Buy → Buy | Get Alert |
03/15/2023 | Buy Now | 404.35% | UBS | Colin Bristow | $31 → $29 | Maintains | Buy | Get Alert |
03/10/2023 | Buy Now | 491.3% | Credit Suisse | Tiago Fauth | $38 → $34 | Maintains | Outperform | Get Alert |
03/10/2023 | Buy Now | 421.74% | HC Wainwright & Co. | Swayampakula Ramakanth | $65 → $30 | Maintains | Buy | Get Alert |
11/09/2022 | Buy Now | 1030.43% | HC Wainwright & Co. | Swayampakula Ramakanth | $80 → $65 | Maintains | Buy | Get Alert |
08/09/2022 | Buy Now | 560.87% | Credit Suisse | Tiago Fauth | $43 → $38 | Maintains | Outperform | Get Alert |
06/06/2022 | Buy Now | 178.26% | Stifel | Bradley Canino | $35 → $16 | Maintains | Buy | Get Alert |
05/19/2022 | Buy Now | 734.78% | Piper Sandler | Christopher Raymond | $70 → $48 | Maintains | Overweight | Get Alert |
03/01/2022 | Buy Now | 526.09% | Stifel | Bradley Canino | $60 → $36 | Maintains | Buy | Get Alert |
12/22/2021 | Buy Now | 334.78% | Jefferies | Michael Yee | $65 → $25 | Downgrade | Buy → Hold | Get Alert |
09/30/2021 | Buy Now | 1743.48% | Stifel | — | — | Initiates | → Buy | Get Alert |
The latest price target for ALX Oncology Holdings (NASDAQ:ALXO) was reported by HC Wainwright & Co. on June 10, 2024. The analyst firm set a price target for $25.00 expecting ALXO to rise to within 12 months (a possible 334.78% upside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for ALX Oncology Holdings (NASDAQ:ALXO) was provided by HC Wainwright & Co., and ALX Oncology Holdings reiterated their buy rating.
The last upgrade for ALX Oncology Holdings Inc happened on December 8, 2023 when Jefferies raised their price target to $18. Jefferies previously had a hold for ALX Oncology Holdings Inc.
The last downgrade for ALX Oncology Holdings Inc happened on March 8, 2024 when Stifel changed their price target from $10 to $14 for ALX Oncology Holdings Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALX Oncology Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALX Oncology Holdings was filed on June 10, 2024 so you should expect the next rating to be made available sometime around June 10, 2025.
While ratings are subjective and will change, the latest ALX Oncology Holdings (ALXO) rating was a reiterated with a price target of $25.00 to $25.00. The current price ALX Oncology Holdings (ALXO) is trading at is $5.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.